Moderator of the session, Emily K. Curran, MD, Assistant Professor of Internal Medicine at the University of Cincinnati Cancer Center, in Ohio, said that the data presented by Dr. Short and colleagues demonstrated very impressive event-free and overall survival rates, especially for a disease that has historically had very poor outcomes.
“Particularly interesting is that these excellent outcomes were obtained mostly without the need for allogeneic stem cell transplant, although longer follow-up is needed to see if these remissions are maintained long-term,” Dr. Curran told The ASCO Post. “Whether this approach will be equivalent to, or perhaps even superior to regimens utilizing ponatinib in combination with intensive chemotherapy backbones (such as ponatinib plus hyperCVAD) is still unknown.”
“Further, the optimal duration of ponatinib maintenance needs to be further investigated,” Dr. Curran continued. “However, these results build upon the data by Foa and colleagues, supporting a ‘chemotherapy-free’ approach for Philadelphia chromosome-positive acute lymphoblastic leukemia.”1
DISCLOSURES: Dr. Curran has served as a consultant or advisor for Servier, Tempus, Pfizer, Kite, Incyte, and Amgen; has received honoraria from Servier; and has participated in expert panels guidelines for Servier
1. Foà R, Bassan R, Vitale A, et al: Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 383:1613-1623, 2020.
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...